Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Medicare Rx Cards May Negatively Affect Manufacturer Profits – McClellan

Executive Summary

Medicare drug card discounts and transparent drug prices could negatively affect pharmaceutical manufacturers' profits in certain drug classes, CMS Administrator McClellan told a press briefing May 5

You may also be interested in...



Wyeth Protonix Is Price Leader For PPIs Under Medicare Discount Cards

Wyeth's Protonix is carrying the best price for prescription proton pump inhibitors under the Medicare drug discount card program

Wyeth Protonix Is Price Leader For PPIs Under Medicare Discount Cards

Wyeth's Protonix is carrying the best price for prescription proton pump inhibitors under the Medicare drug discount card program

Merck Vioxx Is Lowest-Priced COX-2 Through Medicare Card Program

Merck is positioning Vioxx as the lowest-cost COX-2 inhibitor through the Medicare drug discount card program

Latest Headlines
See All
UsernamePublicRestriction

Register

PS043936

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel